Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1259-1268

  Harris, Stephanie A ^a   Meyer, Joel ^a   Satti, Iman ^a   Marsay, Leanne ^a   Poulton, Ian D ^a   Tanner, Rachel ^a   Minassian, Angela M ^a   Fletcher, Helen A ^a   Mcshane, Helen ^a  

^a NIHR Biomedical Researcg Centre   (United Kingdom)

Author keywords

human BCG challenge; MVA85A; tuberculosis; vaccine

Indexed keywords

BCG VACCINE; MVA85A VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIMYCOBACTERIAL IMMUNITY; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; DNA EXTRACTION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HISTORY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNITY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MALE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY; VACCINATION; VOLUNTEER;

HUMAN BCG CHALLENGE; MVA85A; TUBERCULOSIS; VACCINE;

ADOLESCENT; ADULT; BCG VACCINE; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SKIN; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS VACCINES; YOUNG ADULT;

EID: 84897425594     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit647     Document Type: Article

References (32)

1. WHO. Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 11 June 2013.
2. Brennan MJ, Thole J. Tuberculosis vaccines: A strategic blueprint for the next decade. Tuberculosis Edinburgh: Elsevier, 2012; 92:S6-13.
3. Stylianou E, Pepponi I, Van Dolleweerd CJ, Paul MJ, Ma JK, Reljic R. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice. Vaccine 2011; 29:2279-86.
4. Williams A, Hatch GJ, Clark SO, et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 2005; 85:29-38.
5. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009; 77:3364-73.
6. Verreck FAW, Vervenne RAW, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PloS one 2009; 4:e5264.
7. Worku S, Hoft DF. In vitro measurement of protective mycobacterial immunity antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guerin. Clin Infect Dis 2000; 63110:257-61.
8. Li Q, Whalen CC, Albert JM, et al. Differences in rate and variability of intracellular growth of a panel of Mycobacterium tuberculosis clinical isolates within a human monocyte model. Infect Immun 2002; 70: 6489-93.
9. Marsay L, Matsumiya M, Tanner R, et al. Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb). Tuberculosis Edinburgh: Elsevier, 2013; 93:551-7.
10. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011; 11:57-64.
11. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: A review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-85.
12. Statler J, Mammen M, Lyons A, SunW. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound 2008; 36: 413-7.
13. Marwick C. Volunteers in typhoid infection study will aid future vaccine development. JAMA 1998; 279:1423-4.
14. Minassian AM, Satti I, Poulton ID, Meyer J, Hill AVS, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis 2012; 205:1035-42.
15. McShane H, Brookes R, Gilbert SC, Hill AVS, Mmun INI. Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69:681-6.
16. Minassian AM, Ronan EO, Poyntz H, Hill AVS, McShane H. Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. PloS one 2011; 6:e19840.
17. Talbot EA, Williams DL, Frothingham R, Talbot EA, Williams DL. PCR identification of Mycobacterium bovis PCR identification of Mycobacterium bovis BCG. J Clin Microbio 1997; 35:566.
18. Meyer J, Harris SA, Satti I, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine 2013; 31:1026-33.
19. Wallis RS, Palaci M, Vinhas S, et al. A whole blood bactericidal assay for tuberculosis. J Infect Dis, 2001; 183:1300-3.
20. Cunha AJLA, Anna CCS, Mannarino R, Labanca TC, Ferreira S, March MFBP. Adverse effects of BCG revaccination: A report on 13 cases from Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2002; 6:1110-3.
21. Dourado I, Rios MH, Pereira SMM, et al. Rates of adverse reactions to first and second doses of BCG vaccination: Results of a large community trial in Brazilian school children. Int J Tuberc Lung Dis 2003; 7:399-402.
22. Pathan AA, Minassian AM, Sander CR, et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 2012; 30:5616-24.
23. SSI. Description of BCG VACCINE SSI. http://www.ssi.dk/English/Vaccines/ BCG Vaccine Danish Strain 1331/Discription of BCG Vaccine SSI.aspx. Accessed 12 June 2013.
24. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4.
25. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-8.
26. Fletcher HA, Tanner R, Wallis R, et al. Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with BCG. Clin Vaccine Immunol 2013; 20:1683-9.
27. Worku S, Hoft DF. Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth. Infect Immun 2003; 71: 1763-73.
28. Kampmann B, Tena GN, Mzazi S, Eley B, Young DB, Levin M. Novel human in vitro system for evaluating antimycobacterial vaccines. Infect Immun 2004; 71:6401-7.
29. Cheon S, Kampmann B, Hise AG, et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 2004; 9:901-7.
30. Williams A, Goonetilleke NP, Mcshane H, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005; 73:3814-6.
31. Goonetilleke NP, Mcshane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171:1602-9.
32. B.C.G. and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1963; 1:973-8.